LEOCLAN Co. Ltd. AI Stock Analysis
Want to see JP:7681 full AI Analyst Report?
LEOCLAN Co. Ltd. (7681) AI Stock Analysis
LEOCLAN Co. Ltd.
(TSE/TYO:7681)
The overall score of 69 is primarily driven by excellent cash flow generation, impressive revenue growth, and an attractive fundamental valuation. However, this optimism is notably limited by poor technical indicators and downward price trends, signaling caution for near-term momentum.
LEOCLAN Co. Ltd. (7681) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.12B
- Dividend Yield
- 1.97%
- Average Volume (3M)
- 1,504
- Price to Earnings (P/E)
- 14.7
- Beta (1Y)
- -0.13
- Revenue Growth
- 118.29%
- EPS Growth
- 125.76%
- Country
- Japan
- Employees
- 155
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
LEOCLAN Co. Ltd. Business Overview & Revenue Model
Company Description
LEOCLAN Co.,Ltd. operates as a medical equipment trading firm, addressing diverse needs across medical care, welfare, and general health sectors. Its operations are structured into three main divisions: Medical Total Solutions Business, Remote Image...
LEOCLAN Co. Ltd. Financial Statement Overview
Summary
Strong financial performance highlighted by massive revenue expansion and a robust rebound in cash flow, though slightly offset by structurally thin profit margins and elevated leverage.
Income Statement
82Very PositiveBalance Sheet
70PositiveCash Flow
88Very Positive| Breakdown | TTM | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.47B | 46.91B | 21.49B | 19.80B | 26.63B | 29.77B |
| Gross Profit | 4.99B | 6.15B | 2.74B | 2.62B | 2.82B | 3.06B |
| EBITDA | 916.42M | 1.24B | 400.58M | 375.47M | 553.93M | 789.05M |
| Net Income | 115.68M | 346.69M | 152.78M | 136.06M | 271.31M | 437.05M |
Balance Sheet | ||||||
| Total Assets | 22.30B | 22.73B | 10.91B | 10.66B | 14.75B | 13.52B |
| Cash, Cash Equivalents and Short-Term Investments | 8.78B | 6.45B | 4.78B | 5.57B | 5.54B | 5.48B |
| Total Debt | 4.90B | 4.66B | 7.19M | 12.57M | 5.67M | 99.82M |
| Total Liabilities | 16.28B | 16.65B | 5.09B | 4.93B | 9.02B | 7.98B |
| Stockholders Equity | 5.83B | 5.88B | 5.63B | 5.57B | 5.57B | 5.38B |
Cash Flow | ||||||
| Free Cash Flow | -116.70M | 1.03B | -116.70M | 17.72M | 291.06M | 215.57M |
| Operating Cash Flow | -86.65M | 1.66B | -86.65M | 33.08M | 341.56M | 242.36M |
| Investing Cash Flow | -619.82M | -4.33B | -619.82M | 100.75M | -82.01M | -49.96M |
| Financing Cash Flow | -100.73M | 4.35B | -100.73M | -97.22M | -202.31M | -120.93M |
LEOCLAN Co. Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7681, the sentiment is Negative. The current price of 864.00 is below the 20-day moving average (MA) of 888.90, below the 50-day MA of 942.84, and below the 200-day MA of 909.93, indicating a bearish trend. The MACD of -28.76 indicates Negative momentum. The RSI at 45.08 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7681.
LEOCLAN Co. Ltd. Peers Comparison
Overall Rating
JP:768169Neutral
JP:777644Neutral
JP:497842Neutral
JP:777442Neutral
JP:375040Underperform
JP:459939Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | JPY 5.12B | 14.74 | ― | 1.97% | 118.29% | 125.76% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | JPY 5.63B | -4.61 | ― | ― | -49.43% | -3.77% | |
| 42Neutral | JPY 11.22B | -24.14 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 25.18B | -70.06 | ― | ― | 17.05% | 10.47% | |
| 40Underperform | JPY 6.78B | -13.82 | ― | ― | 101.85% | 73.33% | |
| 39Underperform | JPY 7.65B | -4.11 | ― | ― | ― | 4.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7681 | LEOCLAN Co. Ltd. | 864.00 | -44.28 | -4.87% | |
| JP:3750 | Cytori Cell Research Institute, Inc. | 759.00 | -55.00 | -6.76% | |
| JP:4599 | StemRIM Inc. | 122.00 | -157.00 | -56.27% | |
| JP:4978 | ReproCELL Inc. | 105.00 | -50.00 | -32.26% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 620.00 | 134.00 | 27.57% | |
| JP:7776 | CellSeed Inc. | 142.00 | -152.00 | -51.70% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026